Expert dialogue: Neuroendocrine tumours of the lungs and gastroenteropancreatic system;Expertendialog: Neuroendokrine Tumore der Lunge und des gastroenteropankreatischen Systems

Pneumologie

Volumn 66, Issue 1, 2012, Pages 44-48

  Horsch D ^a   Sayeg, Y ^b   Bonnet, R ^b   Kammerer D ^c   Presselt, N ^d   Baum, R P ^e  

^a Klinik fur Innere Medizin   (Germany)

^b Beatmungsmedizin und Allgemeine Innere Medizin   (Germany)

^c Klinik fur Allgemein und Viszeralchirurgie   (Germany)

^d Klinik für Thorax und Gefchirurgie   (Germany)

^e ZENTRALKLINIK BAD BERKA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; GALLIUM 68; SOMATOSTATIN RECEPTOR;

ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GASTROINTESTINAL TUMOR; GERMANY; HUMAN; INCIDENCE; LUNG TUMOR; NEUROENDOCRINE TUMOR; PANCREAS ISLET CELL TUMOR; PARANEOPLASTIC SYNDROME; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SYSTEMIC THERAPY; TUMOR DIAGNOSIS;

EXPERT TESTIMONY; GASTROINTESTINAL NEOPLASMS; HUMANS; LUNG NEOPLASMS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS;

EID: 84856007087     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0031-1291478     Document Type: Article

References (26)

1. Gosney J, Travis WD. Pathology and genetics: tumors of the lung, pleura, thymus and heart. In: Travis W, Brambilla E, Mller-Hermelink H, Harris C. eds. World Health Organization classification of tumors. Lyon, France IARC: 2004; 76 77
2. Travis WD, Rush W, Flieder DB et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol: 1998; 22 934 944 (Pubitemid 28364493)
3. Naalsund A, Rostad H, Strm EH et al. Carcinoid lung tumors incidence, treatment and outcomes: a population-based study. Eur J Cardiothorac Surg: 2011; 39 565 569
4. Cardillo G, Sera F, Di Martino M et al. Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thorac Surg: 2004; 77 1781 1785 (Pubitemid 38530025)
5. Gustafsson BI, Kidd M, Chan A et al. Bronchopulmonary neuroendocrine tumors. Cancer: 2008; 113 5 21 (Pubitemid 351976381)
6. DeLellis RA, Shin SI. Chapter 9: Immunohistology of endocrine tumors. in: Dabbs ID. ed. Immunohistochemistry. New York Churchill Livingstone: 2006; 267 276
7. Travis WD, Brambilla E, Noguchi M et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol: 2011; 6 244 248
8. Rindi G. The ENETS guidelines: the new TNM classification system. Tumori: 2010; 96 806 809
9. Phan AT, Oberg K, Choi J et al. North American Neuroendocrine Tumor Society (NANETS): NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas: 2010; 39 784 798
10. Kaemmerer D, Peter L, Lupp A et al. Molecular imaging with Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging: 2011; 38 1659 1668
11. Baum RP, Prasad V, Hommann M et al. Receptor PET/CT imaging of neuroendocrine tumors. Recent Results Cancer Res: 2008; 170 225 242
12. Vinik AI, Woltering EA, Warner RR et al. North American Neuroendocrine Tumor Society (NANETS): NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas: 2010; 39 713 734
13. Ambrosini V, Castellucci P, Rubello D et al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun: 2009; 30 281 286
14. Jindal T, Kumar A, Venkitaraman B et al. Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids. Korean J Intern Med: 2010; 25 386 391
15. berg K, Astrup L, Eriksson B et al. Nordic NE Tumour Group: Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Acta Oncol: 2004; 617 636
16. Stamatis G, Freitag L, Greschuchna D. Limited and radical resection for tracheal and bronchopulmonary carcinoid tumour. Report on 227 cases. Eur J Cardiothorac Surg: 1990; 4 527 532
17. Aubry MC, Thomas CF Jr, Jett JR et al. Significance of multiple carcinoid tumors and tumorlets in surgical lung specimens: analysis of 28 patients. Chest: 2007; 131 1635 1643 (Pubitemid 46981614)
18. Escalon J, Detterbeck FC. Carcinoid Tumors. In Shields TW, LoCicero JIII, Reed CE, Feins RH. General Thoracic Surgery. 7th edition. Philadelphia Lippincott Williams & Wilkins: 2009; 1539 1554
19. Modlin IM, Pavel M, Kidd M et al. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther: 2010; 31 169 188
20. Imhof A, Brunner P, Marincek N et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol: 2011; 29 2416 2423
21. van Essen M, Krenning EP, Bakker WH et al. Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. Eur J Nucl Med Mol Imaging: 2007; 34 1219 1227 (Pubitemid 47290659)
22. Yamazaki S, Sekine I, Matsuno Y et al. Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer: 2005; 49 217 223 (Pubitemid 40966750)
23. Ekeblad S, Sundin A, Janson ET et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res: 2007; 13 2986 2991 (Pubitemid 46849574)
24. Yao JC, Shah MH, Ito T et al. RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med: 2011; 364 514 523
25. Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med: 2011; 364 501 513
26. Wolin EM, Fazio N, Saletan S et al. Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumours: Analysis by primary tumour site from RADIANT-2. J Clin Oncol: 2011; 29 (suppl; abstr 4075)